Patients with severe exacerbations (requiring hospitalisation or ER visit) · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief leads to lower patients with severe exacerbations (requiring hospitalisation or ER… compared with higher‐dose ICS/LABA + SABA (high certainty).
1 finding from 1 review
OR 0.72 [0.57, 0.9]
7768 participants
High
Number of participants experiencing one or more episode requiring treatment with oral steroids · children with asthma
Anti‐leukotrienes & ICS may leads to lower participants with one or more exacerbations requiring oral… compared with higher dose ICS (low certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · children with asthma
Anti‐leukotrienes & ICS may leads to higher participants with exacerbations requiring hospital admission compared with higher dose ICS (low certainty).
1 finding from 1 review
Bleeding: Numbers of patients with at least one significant bleeding event · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in bleeding: Numbers of patients with at least one significant bleeding… compared with higher transfusion threshold (20,000 or 30,000) (moderate certainty).
1 finding from 1 review
Mortality: secondary to bleeding · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in mortality: secondary to bleeding compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Presence/absence of HSV oral lesions · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)
Prophylactic valaciclovir (lower dose) showed no clear difference in presence/absence of HSV oral lesions compared with prophylactic valaciclovir (higher dose); GRADE not reported.
1 finding from 1 review
Viral isolates · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)
1 finding from 1 review
Orlowski 2004: 182 throat swabs performed for patients receiving 500 mg of valaciclovir (n = 40) and 198 swabs for those receiving 1000 mg (n = 41); all of the cultures proved negative (1 trial, 81; not estimable).
1 study · 81 participants
GRADE not reported
Adverse effects · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)
1 finding from 1 review
One study reported adverse effects (Warkentin 2002). Twenty patients allocated to receive high dose valaciclovir reported adverse effects (42%); for the low dose group this number was 27 (52%). Adverse effects were…
1 study · 100 participants
GRADE not reported
Underweight · healthy, full‐term (37 to 42 weeks), formula‐fed infants
1 finding from 1 review
Wasting · healthy, full‐term (37 to 42 weeks), formula‐fed infants
1 finding from 1 review
Overweight · healthy, full‐term (37 to 42 weeks), formula‐fed infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Obesity · healthy, full‐term (37 to 42 weeks), formula‐fed infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · healthy, full‐term (37 to 42 weeks), formula‐fed infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · healthy, full‐term (37 to 42 weeks), formula‐fed infants
Standard‐protein formula showed no clear difference in adverse events compared with low‐protein formula (low certainty).
1 finding from 1 review
Stunting · healthy, full‐term (37 to 42 weeks), formula‐fed infants
1 finding from 1 review
Wasting · healthy, full‐term (37 to 42 weeks), formula‐fed infants
1 finding from 1 review
Overweight · healthy, full‐term (37 to 42 weeks), formula‐fed infants
It is very uncertain whether high‐protein formula changes overweight compared with standard‐protein formula (very low certainty).
1 finding from 1 review
Obesity · healthy, full‐term (37 to 42 weeks), formula‐fed infants
It is very uncertain whether high‐protein formula changes obesity compared with standard‐protein formula (very low certainty).
1 finding from 1 review
All‐cause mortality · healthy, full‐term (37 to 42 weeks), formula‐fed infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · healthy, full‐term (37 to 42 weeks), formula‐fed infants
High‐protein formula showed no clear difference in adverse events compared with standard‐protein formula (low certainty).
1 finding from 1 review